WO2002036628A3 - Nouveaux polypeptides $g(b) interferon multimeres - Google Patents

Nouveaux polypeptides $g(b) interferon multimeres Download PDF

Info

Publication number
WO2002036628A3
WO2002036628A3 PCT/DK2001/000723 DK0100723W WO0236628A3 WO 2002036628 A3 WO2002036628 A3 WO 2002036628A3 DK 0100723 W DK0100723 W DK 0100723W WO 0236628 A3 WO0236628 A3 WO 0236628A3
Authority
WO
WIPO (PCT)
Prior art keywords
interferon beta
polypeptides
beta polypeptides
multimeric
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2001/000723
Other languages
English (en)
Other versions
WO2002036628A2 (fr
Inventor
Claus Bornaes
Kim Vilbour Andersen
Paul Baad Rasmussen
Anders Hjelholt Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen ApS
Original Assignee
Maxygen ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen ApS filed Critical Maxygen ApS
Priority to EP01980206A priority Critical patent/EP1334128A2/fr
Priority to AU2002212107A priority patent/AU2002212107A1/en
Publication of WO2002036628A2 publication Critical patent/WO2002036628A2/fr
Publication of WO2002036628A3 publication Critical patent/WO2002036628A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un polypeptide β interféron multimère à chaîne unique. Ce polypeptide comprend au moins deux monomères liés via une liaison peptidique ou un lieur peptidique. Au moins un des monomères est un monomère β interféron comprenant une séquence d'acides aminés qui diffère de celle du β interféron de l'homme, de type sauvage dans au moins un site de glycosylation introduit. L'invention traite également de procédés de préparation de ces polypeptides ou conjuguats, et de l'utilisation de ces polypeptides en thérapie, en particulier pour traiter la sclérose en plaques.
PCT/DK2001/000723 2000-11-02 2001-11-01 Nouveaux polypeptides $g(b) interferon multimeres Ceased WO2002036628A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01980206A EP1334128A2 (fr) 2000-11-02 2001-11-01 Nouveaux polypeptides $g(b) interferon multimeres
AU2002212107A AU2002212107A1 (en) 2000-11-02 2001-11-01 New multimeric interferon beta polypeptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001646 2000-11-02
DKPA200001646 2000-11-02

Publications (2)

Publication Number Publication Date
WO2002036628A2 WO2002036628A2 (fr) 2002-05-10
WO2002036628A3 true WO2002036628A3 (fr) 2003-01-03

Family

ID=8159820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2001/000723 Ceased WO2002036628A2 (fr) 2000-11-02 2001-11-01 Nouveaux polypeptides $g(b) interferon multimeres

Country Status (3)

Country Link
EP (1) EP1334128A2 (fr)
AU (1) AU2002212107A1 (fr)
WO (1) WO2002036628A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
UA86749C2 (en) * 2002-09-27 2009-05-25 Байоджен Айдек Ма Инк. THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-в
FR2851471B1 (fr) * 2003-02-24 2006-07-28 Synt Em Composes comprenant au moins une substance active et au moins un vecteur relies par un agent de liaison, leurs utilisations et lesdits agents de liaison
EP2327724A3 (fr) * 2004-02-02 2011-07-27 Ambrx, Inc. Polypeptides d'hormone de croissance humaine et leur utilisations
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63267296A (ja) * 1986-03-14 1988-11-04 Toray Ind Inc インタ−フエロン結合体およびその製造方法
WO1999002710A1 (fr) * 1997-07-10 1999-01-21 Beth Israel Deaconess Medical Center Production et utilisation de multimeres de proteines recombinees a activite biologique modifiee
WO1999003887A1 (fr) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derives d'hormone de croissance et proteines associees
US5908626A (en) * 1995-12-28 1999-06-01 Tanox, Inc. Hybrid with interferon-β and an immunoglobulin Fc joined by a peptide linker
WO1999038891A1 (fr) * 1998-02-03 1999-08-05 Beth Israel Deaconess Medical Center Erythropoietine multimere a activite biologique modifiee
WO2000023472A2 (fr) * 1998-10-16 2000-04-27 Biogen, Inc. Proteines de fusion a interferon beta et leurs utilisations
WO2000023114A2 (fr) * 1998-10-16 2000-04-27 Biogen, Inc. Conjugues polymere-interferon beta 1a et leurs utilisations
WO2001015736A2 (fr) * 1999-08-27 2001-03-08 Maxygen Aps Nouvelles molecules analogues a l'interferon beta

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63267296A (ja) * 1986-03-14 1988-11-04 Toray Ind Inc インタ−フエロン結合体およびその製造方法
US5908626A (en) * 1995-12-28 1999-06-01 Tanox, Inc. Hybrid with interferon-β and an immunoglobulin Fc joined by a peptide linker
WO1999002710A1 (fr) * 1997-07-10 1999-01-21 Beth Israel Deaconess Medical Center Production et utilisation de multimeres de proteines recombinees a activite biologique modifiee
WO1999003887A1 (fr) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derives d'hormone de croissance et proteines associees
WO1999038891A1 (fr) * 1998-02-03 1999-08-05 Beth Israel Deaconess Medical Center Erythropoietine multimere a activite biologique modifiee
WO2000023472A2 (fr) * 1998-10-16 2000-04-27 Biogen, Inc. Proteines de fusion a interferon beta et leurs utilisations
WO2000023114A2 (fr) * 1998-10-16 2000-04-27 Biogen, Inc. Conjugues polymere-interferon beta 1a et leurs utilisations
WO2001015736A2 (fr) * 1999-08-27 2001-03-08 Maxygen Aps Nouvelles molecules analogues a l'interferon beta

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 013, no. 079 (C - 571) 22 February 1989 (1989-02-22) *

Also Published As

Publication number Publication date
WO2002036628A2 (fr) 2002-05-10
AU2002212107A1 (en) 2002-05-15
EP1334128A2 (fr) 2003-08-13

Similar Documents

Publication Publication Date Title
EP2145897A3 (fr) Procédés thérapeutiques et compositions basées sur des protéines serrate et acides nucléiques
WO2005021579A3 (fr) Peptides mimetiques epo et proteines de fusion
YU48703A (sh) Novi interferonu beta-slični molekuli
WO2003037932A3 (fr) Polypeptides du facteur vii de coagulation humain
UA91820C2 (ru) Терапевтическое применение вариантов хемокинов
BG104266A (en) Aminoterminally incised mcp-2 as haemokin antagonists
WO2002036628A3 (fr) Nouveaux polypeptides $g(b) interferon multimeres
WO2005123771B1 (fr) Peptides oligomeres et leur utilisation pour traiter des infections a vih
HUP0400703A2 (hu) Csökkentett immunogenitású módosított eritropoietin (EPO)
WO2003075944A3 (fr) Molecules de type interferon beta destinees au traitement des accidents vasculaires cerebraux
WO2004005317A3 (fr) Dimeres derivant de la thrombine
WO2003016342A3 (fr) Antigenes tumoraux pour la prevention et/ou le traitement du cancer
MXPA02012308A (es) Nuevo interferon para el tratamiento de esclerosis multiple.
WO2002002148A3 (fr) Compositions de therapie genique renfermant deux genes recombines, et methodes d'utilisation correspondantes
WO2004033705A3 (fr) Antagonistes des interferons viraux et utilisations de ceux-ci
GB0001712D0 (en) Therapeutic peptides
WO2003014293A3 (fr) Nouveaux analogues de polypeptides et proteines hybrides et leurs procedes d'utilisation
WO1999031229A3 (fr) Peptides et acides nucleiques derives d'eisenia foetida et leur utilisation
EP0717752A4 (fr) Composes therapeutiques
EP2143730A3 (fr) Peptides modifiés et leur utilisation pour le traitement des maladies auto-immunes
WO2003087137A3 (fr) Nouvelles utilisations therapeutiques de tri-, tetra-, penta-, et polypeptides
CA2083286A1 (fr) Fibrinogenogenases recombinants, leur preparation et leur utilisation
WO2002100897A3 (fr) Complexes moleculaires brca1/acc alpha, applications diagnostiques et therapeutiques
CA2247998A1 (fr) Fragments de recepteur du complement de type 1 et leurs utilisations
WO2004089980A3 (fr) Vaccin preventif contre le cancer

Legal Events

Date Code Title Description
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001980206

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001980206

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001980206

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP